Clinical trials: Sepsis, Severe
Sepsis
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
- Trial name
- NCT00143611
- Testing
- Resatorvid
- Where
- 144 sites in United States, Australia and 15 more
- Volunteers
- 277 people
- Sponsor
- Takeda
Sepsis, Acute Infection
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.
- Trial name
- NCT06665542
- Where
- 8 sites in United States, Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Severe Sepsis, Septic Shock
Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings…
- Trial name
- AdrenOSS (NCT02393781)
- Where
- 24 sites in Belgium, France and 3 more
- Volunteers
- 596 people
- Sponsor
- Sphingotec GmbH
Sepsis
Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis
The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.
- Trial name
- NCT00037687
- Testing
- rPAF-AH
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- ICOS Corporation
Sepsis, Severe Sepsis
RCT of Sepsis Machine Learning Algorithm
The focus of this study will be to conduct a prospective, multi-center randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a machine-learning…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03882476
- Testing
- InSight
- Volunteers
- healthy volunteers welcome
- Sponsor
- Dascena
Severe Sepsis
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis…
- Trial name
- ReActIF- LTO (NCT06143137)
- Where
- 2 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Artcline GmbH
Sepsis, Septic Shock
An Algorithm Driven Sepsis Prediction Biomarker
A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated.
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- NCT03015454
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Dascena
Sepsis, Severe
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care.
- Trial name
- ReActiF-ICE (NCT05442710)
- Testing
- ARTICE
- Where
- 20 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Artcline GmbH
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Sepsis, Severe Sepsis
Gram Type Infection-Specific Sepsis Identification Using Machine Learning
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a Gram type infection-specific…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03734484
- Testing
- InSight
- Volunteers
- healthy volunteers welcome
- Sponsor
- Dascena
Sepsis, Infection
The Performance of the Mologic Biomarker Panel in Infection
This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for…
- Trial name
- NCT03217552
- Testing
- Mologic Biomarker Panel
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Mologic Ltd
Severe Sepsis, Septic Shock
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection.
- Trial name
- SCIENS (NCT02246595)
- Testing
- CaCP29
- Where
- 11 sites in Germany
- Volunteers
- 72 people
- Sponsor
- InflaRx GmbH
Severe Sepsis
Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
A recent study has demonstrated that in low respiratory infections, a strategy using prescription of antibiotics based on the pro-calcitonin level allows decreasing recourse to antibiotics by 47% without prognostic modification.
- Trial name
- Pro-SEPS (NCT01025180)
- Testing
- Procalcitonin level
- Where
- 9 sites in France
- Volunteers
- 62 people
- Sponsor
- Brahms France
Sepsis, Septic Shock
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including…
- Conditions
- Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
- Trial name
- NCT03113721
- Where
- 5 sites in United States
- Volunteers
- 571 people
- Sponsor
- Axis Shield Diagnostics Ltd
Sepsis
Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis
The primary objective of this study is to test whether a fluid resuscitation protocol guided by non-invasive hemodynamic measures reduces the progression of organ dysfunction (defined by an increase in the Serial Organ Failure…
- Trial name
- COMMIT (NCT01484106)
- Testing
- Fluid Resuscitation, Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Cheetah Medical Inc.
Sepsis, Adult Disease
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Emergency Department, Severe Sepsis
- Trial name
- NCT04804306
- Testing
- Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Beckman Coulter, Inc.